Company Filing History:
Years Active: 2018
Title: The Innovations of Roberto Depaz
Introduction
Roberto Depaz is an accomplished inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody formulations. His work is characterized by a focus on stability and efficacy in therapeutic applications.
Latest Patents
Roberto holds a patent for a "Stable anti-IFNAR1 formulation." This invention relates to a stable, low viscosity antibody formulation that includes a high concentration of anti-INFAR1 antibody. The formulation comprises about 100 mg/mL to about 200 mg/mL of an antibody or fragment that specifically binds human interferon alpha 1 (INFAR1). Additionally, it contains about 20 mM to about 80 mM of lysine or a salt thereof, about 0.02% to about 0.06% of a surfactant, an uncharged excipient, and a formulation buffer. The invention also encompasses a container, dosage form, and/or kit, as well as methods for making and using the stable antibody formulation.
Career Highlights
Roberto is currently employed at AstraZeneca AB, where he continues to innovate in the field of biopharmaceuticals. His expertise in antibody formulation has positioned him as a valuable asset to the company. With a focus on creating effective therapeutic solutions, he has contributed to advancing the understanding of antibody stability and formulation.
Collaborations
Roberto has worked alongside talented colleagues, including Natalie DeJesus and Jared Samuel Bee. Their collaborative efforts have fostered an environment of innovation and creativity, leading to advancements in their respective fields.
Conclusion
Roberto Depaz is a notable inventor whose work in stable antibody formulations has the potential to impact therapeutic applications significantly. His contributions to AstraZeneca AB and the field of biotechnology highlight the importance of innovation in developing effective medical solutions.